How The Failure Of US PBM Reform Shaped Sanofi’s Decision To Exit Diabetes R&D

And how in contrast, Novo Nordisk is launching its oral GLP-1 agonist for diabetes at a price that may set up 'business as usual' tensions with pharmacy benefit managers and payers.